AMG 728 / Amgen - LARVOL DELTA

PD-L1-dependent 4-1BB costimulation enhances anti-tumor efficacy and T cell persistence as monotherapy or in combination with tarlatamab (AACR 2026) - "Notably, AMG 728 treatment led to a significant increase in central memory T cells in the tumors from tarlatamab-treated mice. Collectively, these findings suggest that the addition of AMG 728 to tarlatamab represents a rational combination strategy that enhances T cell activation and longevity, resulting in improved antitumor activity and survival."

Clinical • Combination therapy • IO biomarker • Monotherapy • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • CD8 • DLL3 • PD-L1